KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Shares Issued (2016 - 2024)

Novavax (NVAX) has 15 years of Shares Issued data on record, last reported at $256.4 million in Q2 2024.

  • For Q2 2024, Shares Issued rose 313.66% year-over-year to $256.4 million; the TTM value through Mar 2025 reached $256.4 million, up 48.99%, while the annual FY2024 figure was $263.3 million, 26.92% down from the prior year.
  • Shares Issued reached $256.4 million in Q2 2024 per NVAX's latest filing, up from $6.9 million in the prior quarter.
  • Across five years, Shares Issued topped out at $538.0 million in Q3 2021 and bottomed at $1.5 million in Q2 2020.
  • Average Shares Issued over 5 years is $177.2 million, with a median of $103.2 million recorded in 2023.
  • Peak YoY movement for Shares Issued: surged 891040.0% in 2020, then tumbled 87.04% in 2021.
  • A 5-year view of Shares Issued shows it stood at $428.6 million in 2020, then increased by 25.53% to $538.0 million in 2021, then tumbled by 87.02% to $69.8 million in 2022, then skyrocketed by 47.82% to $103.2 million in 2023, then skyrocketed by 148.34% to $256.4 million in 2024.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $256.4 million in Q2 2024, $6.9 million in Q1 2024, and $103.2 million in Q4 2023.